United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 ml - hydrocortisone butyrate ointment, 0.1% and hydrocortisone butyrate cream usp, 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. hydrocortisone butyrate topical solution, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of seborrheic dermatitis. none.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 ml - hydrocortisone butyrate solution, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of seborrheic dermatitis. none.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 g - hydrocortisone butyrate cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. none.

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate 1 mg in 1 g - hydrocortisone butyrate ointment, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. none.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone butyrate - unii:05rmf7ypwn) - hydrocortisone butyrate 1.0 mg in 1 g - hydrocortisone butyrate cream usp, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate lotion is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. none. pregnancy category c.   there are no adequate and well-controlled studies in pregnant women. therefore, hydrocortisone butyrate lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate lotion (25 g lotion). systemic embryofetal development studies were conducted in rats and rabbits

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate cream usp, 0.1% (lipophilic) is indicated for: - relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults. - the topical treatment of mild to moderate atopic dermatitis in pediatric patients 3 months to 18 years of age. none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. therefore, hydrocortisone butyrate cream usp, 0.1% (lipophilic) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topic

United States - English - NLM (National Library of Medicine)

sola pharmaceuticals - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - none. 8.1 pregnancy pregnancy category c there are no adequate and well-controlled studies in pregnant women. therefore, hydrocortisone butyrate lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m 2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate lotion (25 g lotion). systemic embryofetal development studies were conducted in rats and rabbits. subcutaneous doses of 0.6, 1.8 and 5.4 mg/kg/day hydrocortisone butyrate were administered to pregnant female rats during gestation d

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - none. 8.1 pregnancy pregnancy category c there are no adequate and well-controlled studies in pregnant women. therefore, hydrocortisone butyrate lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m 2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate lotion (25 g lotion). systemic embryofetal development studies were conducted in rats and rabbits. subcutaneous doses of 0.6, 1.8 and 5.4 mg/kg/day hydrocortisone butyrate were administered to pregnant female rats during gestation d

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - hydrocortisone butyrate (unii: 05rmf7ypwn) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone butyrate cream (lipid), 0.1% is indicated for: none. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. therefore, hydrocortisone butyrate cream (lipid), 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. note: the animal multiples of human exposure calculations in this label were based on body surface area comparisons for an adult (i.e., mg/m2 /day dose comparisons) assuming 100% human percutaneous absorption of a maximum topical human dose (mthd) for hydrocortisone butyrate cream (25 g). systemic embryofetal development studies were conducted in rats and rabbits. subcutaneous doses of 0.6, 1.8, and 5.4 mg/kg/day hydrocortisone butyrate were administered to preg